Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors

Details for Australian Patent Application No. 2004267030 (hide)

Owner Amgen, Inc. Medarex, Inc.

Inventors Treanor, James J. S.; Inoue, Heather; Martin, Frank; Huang, Haichun; Wild, Kenneth D.; Zhang, Tie J.

Agent Wrays

Pub. Number AU-B-2004267030

PCT Pub. Number WO2005/019266

Priority 60/487,431 15.07.03 US

Filing date 15 July 2004

Wipo publication date 3 March 2005

Acceptance publication date 17 June 2010

International Classifications

C07K 16/22 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

G01N 33/53 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Immunoassay

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2005/019266 Priority application(s): WO2005/019266

27 April 2006 Amendment Made

  The nature of the amendment is: Add the co-applicant Medarex, Inc.

17 June 2010 Application Accepted

  Published as AU-B-2004267030

14 October 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004267038-Systems and methods for producing fluorocarbons

2004267027-6-(2,2,2-trifluoroethylamino)-7-chloro-2, 3,4,5-tetrahydro-1H-benzo(d)azepine as a 5-HT2c receptor agonist